1. Longitudinal dynamics of circulating tumor DNA for treatment monitoring in patients with breast cancer recurrence.
- Author
-
Yoo, Tae-Kyung Robyn, Lee, Ji-Young, Park, Hwan, Cho, Whi-Kyung, Jeon, Seyeon, Jun, Ha Ra, Lee, Sae Byul, Chung, Il Yong, Kim, Hee Jeong, Ko, Beom Seok, Lee, Jong Won, Son, Byung Ho, Ahn, Sei-Hyun, Jeong, Jae Ho, Kim, Jeong Eun, Ahn, Jin-Hee, Jung, Kyung Hae, Kim, Sung-Bae, Lee, Hee Jin, and Gong, Gyungyub
- Subjects
- *
CIRCULATING tumor DNA , *CANCER relapse , *BREAST cancer , *METASTATIC breast cancer , *CANCER patients , *PATIENT monitoring , *IRINOTECAN - Abstract
The prevalence and dynamics of circulating tumor DNA (ctDNA) in patients with breast cancer recurrence or de novo metastatic cancer were examined in a retrospective analysis of a prospective observational cohort. Twenty-three recurrent/metastatic breast cancer cases (8 locoregional, 15 distant metastasis) were enrolled, and sequential plasma samples were obtained. Anchor mutations were selected from the target sequencing of each patient's primary and/or metastatic tumor. An in-house developed assay (UHS assay) was employed for a tumor-informed ctDNA assay during treatment and follow-up. A median of three (range 1–5) anchor mutations per case were applied for ctDNA detection. ctDNA was detected in 14 (63.6%, 14/22) cases at the time of enrollment and 18 (78.5%, 18/23) cases during follow-up. More anchor mutations and higher tumor burden were significantly related to higher ctDNA positive rates (p-value 0.036, 0.043, respectively). The mean enriched variant allele frequency (eVAF) at each time point was significantly higher for stable or progressive disease responses (ANOVA test p-value < 0.001). Eight patients showed an increase in their ctDNA eVAF prior to clinical progression with a mean lead time of 6.2 months (range 1.5–11 months). ctDNA dynamics measured using personalized assay reflected the clinical course of breast cancer recurrence. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF